Novartis Warping Kickback Standard In FCA Case, DOJ Says
Novartis Pharmaceuticals Corp. has flatly "misstated the law" in its bid to escape a whistleblower's False Claims Act suit alleging illicit kickbacks aimed at boosting Medicare Part D business, the U.S....To view the full article, register now.
Already a subscriber? Click here to view full article